AstraZeneca Pharma India Limited with delayed price, financials, ownership context, and peer links.
Peer links appear when comparable names are available.
Key drivers included a 26% increase in Oncology revenue and substantial growth in Biopharmaceuticals and Rare Diseases segments. The company also secured regulatory approvals for Acalabrutinib and Trastuzumab deruxtecan, alongside strategic initiatives like an AI-enabled lung cancer screening MoU.
Financial highlights are being recalculated.
Financial highlights are being recalculated.